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p27Kip1, a cyclin-cdk inhibitor, is a tumor suppressor. An overwhelming amount of data correlate p27 abundance to tumor 
prognosis in humans. Mouse models have supported the importance of decreasing p27 to tumor incidence. Inactivation of 
most tumor suppressors occurs at the level of gene mutation or silencing, but p27 is regulated posttranscriptionally, and 
how its level is reduced in cancer is largely unknown. Reports on a series of allelic mice with p27 mutations affecting dif-
ferent posttranscriptional regulatory pathways are emerging and being used to examine which pathways are necessary for 
p27 turnover associated with tumor development, with surprising results.Strong prognostic markers that differenti-
ate patient outcomes when analyzing an 
intermediate stage disease are of utmost 
importance in making appropriate thera-
peutic evaluations. The inverse correlation 
between expression of the cdk inhibitor 
p27 and prognosis in a variety of human 
neoplasms, including those of the breast, 
colon, and prostate among others, is well 
known (Blain et al., 2003). Mice with an 
allele that reduces the ability of p27 to 
inhibit cyclin-cdk complexes (∆51, a 51 
amino acid deletion of the amino ter-
minus of the protein) or a complete null 
are larger because of a defect in timely 
exit from the cell cycle. Establishing the 
causal nature between p27 abundance 
with tumor incidence, tumors develop in 
a wide variety of tissues more frequently 
and progress faster in these p27-deficient 
mice challenged by a variety of carcino-
gens, oncogenes, and the loss of other 
tumor suppressors (Blain et al., 2003). 
Although it is well established that p27 is 
a dosage-dependent tumor suppressor, 
two questions have remained—what does 
the reduction of p27 contribute to tumor 
development, and how is the level of p27 
reduced to eliminate its tumor-suppres-
sive function?
Gene mutation or silencing at the 
p27 locus is rare, and abundance of p27 
protein appears to be largely controlled 
by posttranscriptional mechanisms. The 
mechanisms controlling p27 abundance 
range from translational control observed 
in quiescent cells to proteolytic mecha-
nisms operating at specific phases of 
the cell cycle or in specific subcellular 
compartments, such as the cytoplasm 
or nucleus. Focusing on protein turnover 
and localization, three pathways have 
been suggested. The best understood 
is the SCFskp2/cks1 nuclear ubiqui-
tination-dependent turnover pathway in 
S and G2/M cells (Bloom and Pagano, 
2003). In the absence of this pathway, 
p27 levels decrease as cells reenter the 
cell cycle but reaccumulate in S phase 
cells, ultimately leading to aneuploidy 
and problems in G2/M progression cancer cell February 2006 (Nakayama et al., 2004). Unexpectedly, 
mutating threonine 187 to alanine 
(T187A) prevents p27 ubiquitination by 
SCFskp2/cks1, but these cells do not 
share the mitotic phenotype of skp2-
deficient cells (Kossatz et al., 2004). 
Restriction of this p27 turnover pathway 
to S and G2/M cells is explained by the 
growth-dependent accumulation of skp2 
and the requirement for cyclin A-cdk2 to 
present p27 into the SCFskp2/cks1 com-
plex (Hao et al., 2005; Zhu et al., 2004). 
Less understood is a pathway by which 
p27 is exported to the cytoplasm, where 
it may be degraded in a KPC1/2-induced, 
ubiquitin-dependent manner (Kamura et 
al., 2004). In this pathway, p27 is phos-
phorylated on serine 10, which promotes 
CRM1-dependent binding and nuclear 
export. This pathway operates in G1 
cells or cells stimulated to reenter the cell 
cycle from a quiescent state. Additionally, 
Akt-dependent nuclear exclusion can be 
induced by phosphorylation of threonine 
157 (Blain et al., 2003). However, while 
this mechanism explains the regulation 
of p27 in certain human tumors, this site 
is not conserved in the mouse.
Understanding which mechanisms 
are important for reducing p27 during 
tumor development has obvious impor-
tance. In a recent issue of Genes and 
Development, Besson and coworkers 
(Besson et al., 2006) provide convinc-
ing evidence for a serine 10-dependent 
regulatory mechanism affecting p27 
tumor suppressive activity during lung 
tumor development. This is a notable first. 
Using urethane-induced carcinogenesis, 
they show that p27 is a haploinsufficient 
tumor suppressor—heterozygous mice 
develop tumors at the same frequency 
as the complete null and do not lose or 
inactivate the remaining allele, albeit the 
tumors in the heterozygous mice appear 
to progress at a slower rate. During 
this process, serine 10 phosphorylated 
p27 accumulates in the cytoplasm of 
lung tumor cells. Activated ras plays a 
role in this carcinogenic process, and 
the authors demonstrate that K-rasV12 induces cytoplasmic accumulation of p27 
and serine 10 phosphorylation, both of 
which can be increased further by addi-
tion of a proteasome inhibitor. The crux 
of the report of interest to the reader of 
Cancer Cell is that mutating serine 10 to 
alanine reduces the number of tumors 
and the rate at which they grow, and K-
rasV12 cannot induce cytoplasmic local-
ization of p27S10A, arguing that this is 
a bona fide mechanism by which p27 
function is reduced during oncogenesis. 
This mutation does not affect the size of 
the animal, spontaneous pituitary tumor 
development, or fertility (James Roberts, 
personal communication).
However, what may temper the 
momentum to link skp2-induced p27 
turnover to cancer is that the authors 
mentioned the tantalizing (but still 
unpublished) observation that muta-
tion of threonine 187, which eliminates 
SCFskp2/cks1-dependent turnover, 
failed to suppress tumor development. 
While it might be reasonably argued that 
a single example of this is not sufficient 
to diminish the importance of the skp2-
p27 pathway to tumor development, most 
of the evidence linking skp2-induced 
p27 turnover to cancer is indirect. While 
skp2 is oncogenic when overexpressed 
(Latres et al., 2001), skp2-induced p27 
turnover is generally restricted to S and 
G2/M phase of the cell cycle, and skp2 
has more substrates than p27 itself. 
Cancer is a disease reflecting defects 
in the choice cells make to enter or exit 
the cell cycle rather than an aspect of 
the irreversibility of the decision to enter 
the cell cycle.
Thus, this work may presage an inter-
esting paradigm shift from an SCFskp2/
cks1-centric mechanism regulating 
p27 abundance and tumor suppression 
activity toward a serine 10-dependent 
cytosolic localization mechanism. This 
may parallel or overlap the human-spe-
cific threonine 157-dependent cytosolic 
pathway (reviewed in Blain et al., 2003). 
Determining the mechanisms controlling 
serine 10 phosphorylation and the differ-75
	 p r e v i e w sences between G0 and G1 cells affect-
ing the stability and localization of the 
phosphorylated p27 will prove of inter-
est in understanding the role of p27 as 
a tumor suppressor. Additionally, given 
that enforced expression of skp2 leads 
to tumor development, one might wish to 
pursue additional targets of this E3 ligase 
that contribute to its oncogenicity.
Perhaps of lesser importance to 
cancer at this time, but likely to grow 
as more experiments are done, Besson 
also reports the generation of a mutant 
that will not bind to cyclin-cdk complexes. 
An allele with a four amino acid substitu-
tion was made that eliminates cyclin-cdk 
binding (ck−). The crystal structure of 
the SCFskp2/cks1 E3 ligase (Hao et al., 
2005) and the reconstitution experiments 
with catalytically inactive cyclin A-cdk2 
(Zhu et al., 2004) demonstrate that this 
mutation affects cyclin-cdk presentation 
of p27 to the ligase, and it is assumed 
that cyclin-cdk binding is also necessary 
for destabilization of the nonphosphory-
lated S10A protein in the nuclei of quies-
cent cells. Similar to mice with null or ∆51 
alleles, ck− mice are large, suggesting 
that cyclin-cdk binding is the functional 
reason for this phenotype, but the fertility 
and spontaneous tumor phenotype were 
not addressed.
The ck− mouse may play a role in 
unraveling cyclin-cdk-independent func-
tions associated with p27 accumulation 
in tumorigenesis. Through sequences in 
the carboxyl half of p27, it can interact 
with rho (Besson et al., 2004) and Grb2 
(Moeller et al., 2003). This interaction may 
affect these signaling pathways or their 
biologic outcomes during tumor develop-
ment. A requirement for “some” p27 has 
been suggested for tumor development 76 in mouse ErbB2/Neu breast (Muraoka 
et al., 2002) and Pten-deficient prostate 
(Gao et al., 2004) cancer models utilizing 
p27∆51 animals. However, these authors 
associated this function with appropriate 
regulation of cyclin D1 levels and kinase 
activity. A potential cytosolic function was 
largely unaddressed. While both the ck− 
mutant and the ∆51 mutant retain the 
carboxyl domains, ck− has the serine 10 
phosphorylation site, which would per-
mit a level of regulation not possible with 
∆51. Thus, the ck− mutant might be able 
to address whether retention of p27 in the 
cytoplasm, if not completely eliminated by 
a pathway involving KPC-induced ubiqui-
tination, has oncogenic cyclin-cdk-inde-
pendent functions.
Armed with the resource of an allel-
ic series of mice, we can now begin to 
understand which of the regulatory mech-
anisms determining p27 expression allow 
its function as a tumor suppressor. While 
these mice will have value for looking at 
cyclin-cdk-independent functions that may 
impact tumorigenesis, equally interesting 
will be their effects on cell differentiation 
and animal development.
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